儿童免疫性血小板减少症中抗血小板抗体的患病率及预后意义
本研究基于TIKI试验队列(N=179)的新诊断儿童ITP患者,采用单克隆抗体固定血小板抗原法检测抗血小板糖蛋白特异性IgM和IgG抗体。结果显示IgM为优势抗体(62%),IgG占10%;观察组中IgM阳性者血小板恢复更快(P=7.1×10-5),可检测到IgG者对IVIg几乎完全反应(N=12,P=.02)。
要点
- 儿童ITP以IgM型抗血小板抗体为主(62%),IgG较少(10%)。
- 观察组中IgM阳性者1年内血小板恢复更快,独立于年龄和感染史。
- 检出IgG抗体的小样本患者对IVIg治疗几乎均完全反应。
核心结论
- 检测循环抗血小板抗体可能有助于新诊断儿童ITP的临床预后判断和治疗决策。
- 更敏感的检测方法可能进一步提升抗体检测的临床价值。
研究设计与样本
- 基于TIKI试验队列,纳入新诊断儿童ITP患者(N=179),随机分至IVIg组或谨慎观察组。
- 采用单克隆抗体固定血小板抗原法检测抗血小板糖蛋白特异性IgM和IgG抗体。
主要发现
- 儿童ITP优势循环抗血小板抗体为IgM(62%),IgG抗体占10%。
- 无IgM血小板抗体者年龄更大且更常为女性。
- IgM抗GP IIb/IIIa抗体与出血严重度增加存在弱关联(P=.03)。
- IgM和IgG抗血小板反应部分重叠,反应常针对多种糖蛋白。
- 观察组中IgM阳性者1年内血小板恢复更快,校正年龄和前期感染后P=7.1×10-5。
关键数值与推荐
- IgM抗血小板抗体阳性率62%,IgG阳性率10%(新诊断儿童ITP,N=179)。
- IgM抗GP IIb/IIIa抗体与出血严重度关联的P=.03。
- 观察组IgM阳性者血小板恢复更快的校正P=7.1×10-5。
- IgG阳性患者对IVIg几乎完全反应:N=12,P=.02。
临床怎么用
- 对新诊断儿童ITP可考虑检测抗血小板糖蛋白特异性IgM/IgG抗体辅助预后判断。
- IgM阳性观察组患者可能血小板恢复更快,可支持谨慎观察策略。
- 检出IgG抗体者可能对IVIg特别有效,可辅助治疗选择。
局限性
- 原文未报告抗体检测的敏感性、特异性或阈值数据。
- IgG阳性亚组样本量小(N=12),结论需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Anti-platelet antibody testing may be useful for the diagnosis and management of childhood immune thrombocytopenia (ITP). OBJECTIVES: Here we aimed to assess the prevalence and prognostic significance of anti-platelet glycoprotein-specific IgM and IgG antibodies. METHODS: Children with newly diagnosed ITP were included at diagnosis and randomized to an intravenous immunoglobulins (IVIg) or careful observation group (TIKI trial). In this well-defined and longitudinally followed cohort (N = 179), anti-platelet glycoprotein-specific IgM and IgG antibodies were determined by monoclonal antibody-immobilization of platelet antigens. RESULTS: The dominant circulating anti-platelet antibody class in childhood ITP was IgM (62% of patients); but IgG antibodies were also found (10%). Children without IgM platelet antibodies were older and more often female. There was weak evidence for an association between IgM anti-GP IIb/IIIa antibodies and an increased bleeding severity (P = .03). The IgM and IgG anti-platelet responses partially overlapped, and reactivity was frequently directed against multiple glycoproteins. During 1-year follow-up, children with IgM antibodies in the observation group displayed a faster platelet recovery compared to children without, also after adjustment for age and preceding infections (P = 7.1 × 10-5 ). The small group of patients with detectable IgG anti-platelet antibodies exhibited an almost complete response to IVIg treatment (N = 12; P = .02), suggesting that IVIg was particularly efficacious in these children. CONCLUSIONS: Testing for circulating anti-platelet antibodies may be helpful for the clinical prognostication and the guidance of treatment decisions in newly diagnosed childhood ITP. Our data suggest that the development of even more sensitive tests may further improve the clinical value of antibody testing.
引用
- Schmidt DE, Heitink-Polle KMJ, Porcelijn L, et al. Anti-platelet antibodies in childhood immune thrombocytopenia: Prevalence and prognostic implications. J Thromb Haemost. 2020. PMID: 32053276. doi:10.1111/jth.14762
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。